人诱导多能干细胞来源血小板的研究进展  

Research progress in research on platelets derived from induced pluripotent stem cells

作　　者：谢月娜 种靖慧 刘军 解金辉 李彤彤[1] 潘彤 Xie Yuena;Chong Jinghui;Liu Jun;Xie Jinhui;Li Tongtong;Pan Tong(Tianjin Blood Center,Tianjin 300110,China)

机构地区：[1]天津市血液中心,天津300110

出　　处：《国际生物医学工程杂志》2022年第5期448-452,共5页International Journal of Biomedical Engineering

基　　金：天津市卫健委科技基金(2012KY28)

摘　　要：目前用于临床输注的血小板来源不足,且输注后有发生同种异体免疫反应和经输血传播感染等风险。近年来人诱导多能干细胞(hiPSCs)来源的血小板成为输血界的研究热点之一,研究显示其有望解决血小板输注的局限性,缓解血小板临床供需矛盾。但目前hiPSCs体外产生功能性血小板的效率尚低,产量和质量距离临床输注标准还有一定差距。主要对hiPSCs来源血小板的相关基础和应用、人类白细胞抗原(HLA)基因沉默的hiPSCs来源血小板的相关研究和hiPSCs血小板制品面临的挑战进行综述,以期为hiPSCs来源血小板的深入研究及未来临床应用提供参考。Currently,there are insufficient sources of platelets for clinical transfusion,and there are risks of alloimmune reactions and transfusion-transmitted infections(TTI)after transfusion.In recent years,platelets derived from human induced pluripotent stem cells(hiPSCs)have become one of the hottest research topics in the transfusion community,and studies have shown that they have the potential to address the limitations of platelet transfusion and alleviate the conflict between platelet supply and demand in clinical settings.However,the efficiency of hiPSCs in producing functional platelets in vitro is still low,and the yield and quality are still far below clinical transfusion standards.In this review,the basis and applications related to hiPSCs-derived platelets,studies related to human leukocyte antigen(HLA)gene-silenced hiPSC-derived platelets,and challenges faced by hiPSCs-derived platelet products were reviewed,providing references for in-depth research and future clinical applications of hiPSCs-derived platelets.

关 键 词：人诱导多能干细胞 血小板 血小板制品 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]